AbbVie (NYSE:ABBV) Given New $265.00 Price Target at Cantor Fitzgerald
AbbVie (NYSE:ABBV – Get Free Report) had its target price boosted by analysts at Cantor Fitzgerald from $240.00 to $265.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “overweight†rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 1.58% from the […]
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.